NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis
BackgroundBrain metastases (BMs) are associated with poor prognosis and significant mortality, and approximately 25% of patients with non–small cell lung cancer (NSCLC) develop BMs. The present study was aimed to understand the relationships between BM and NSCLC and reveal potential biomarkers and t...
Guardado en:
Autores principales: | Lu Peng, Yihao Tao, Rui Wu, Jing Su, Maoyuan Sun, Yuan Cheng, Zongyi Xie, Jinning Mao, Xiaohui Zhan, Guodong Liu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2308467c2aae4f49ae1a3c94ad377e56 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Identification and Validation of TYMS as a Potential Biomarker for Risk of Metastasis Development in Hepatocellular Carcinoma
por: Shuai Li, et al.
Publicado: (2021) -
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
por: Siavash Jabbari, et al.
Publicado: (2011) -
Four long noncoding RNAs act as biomarkers in lung adenocarcinoma
por: Zhang Zhihui, et al.
Publicado: (2021) -
Glutathione peroxidase 4‐dependent glutathione high‐consumption drives acquired platinum chemoresistance in lung cancer‐derived brain metastasis
por: Wenwen Liu, et al.
Publicado: (2021) -
Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
por: Guangchuan Deng, et al.
Publicado: (2021)